This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.


EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution

Active substance: no-carrier-added (n.c.a.) Lutetium-177 (177Lu) chloride

EndolucinBeta® is a radiopharmaceutical precursor and indicated for the radiolabeling of disease-specific carrier molecules in nuclear medicine. These biomolecules have been specifically developed for the radiolabeling with this radionuclide. The emerging radio conjugate is applied in Targeted Radionuclide Therapy, frequently in cancer treatment e.g. for neuroendocrine tumors (NETs). EndolucinBeta® has a half-life of 6.647 days and provides the specific activity of more than 3,000 GBq/mg at Activity Reference Time (ART). EndolucinBeta® contains no metastable 177mLu.

Additional information for Healthcare Professionals

Video – Production of n.c.a. Lutetium-177 / EndolucinBeta® for Targeted Radionuclide Therapy